

REMARKS

A Restriction Requirement under 35 U.S.C. §121 has been entered in the present application. The Restriction Requirement identifies two inventions:

- Group I: Claims 1-31, drawn to a method of treating or preventing a myeloproliferative disease, which comprises administering a selective cytokine inhibitory drug; and
- Group II: Claims 32-40, drawn to a pharmaceutical composition or kit comprising a selective cytokine inhibitory drug.

In order to be fully responsive to the restriction requirement, Applicant provisionally elects Group I (claims 1-31), without prejudice to Applicant's right to prosecute any non-elected subject matter in one or more continuation, continuation-in-part or divisional applications.

Further, Applicant has been required to elect a single species of the compound and second agent. In order to be fully responsive to the requirement, Applicant elects the compound of cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide recited in claim 14 and hydroxyurea recited in claim 9.

No fee is believed to be due in connection with this; however, should any fee be required, Applicant hereby authorizes that such fee be charged to Deposit Account No. 50-3013.

Date: April 11, 2008

Respectfully submitted,

By: Yeah-Sif Moon

(Reg. No.) 52,042

JONES DAY
222 East 41st Street
New York, New York 10017-6702
(212) 326-3939